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Interaction of HLA-DR with an Acidic Face
of HLA-DM Disrupts Sequence-Dependent
Interactions with Peptides
for loading of other peptides and, for most MHCII alleles,
requires the action of DM.
DM is a MHCII-like protein that catalyzes exchange
of peptides in the MHCII groove. In DM0 cells, most
MHCII accumulate at the cell surface loaded with CLIP;
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Summary Little is known about the structure of DM/MHCII com-
plexes. The interaction depends strongly on anchoring
HLA-DM (DM) edits major histocompatibility complex of both molecules in a common membrane or detergent
class II (MHCII)-bound peptides in endocytic compart- micelle (Busch et al., 1998; Weber et al., 2001). Biochem-
ments and stabilizes empty MHCII molecules. Crystal ical studies implicate surfaces with charged and hydro-
structures of DM have revealed similarity to MHCII but phobic residues (Sloan et al., 1995; Ullrich et al., 1997).
not how DM and MHCII interact. We used mutagenesis We have mapped a lateral, DM-interacting surface on
to map a MHCII-interacting surface on DM. Mutations DR that includes acidic and hydrophobic DR residues
on this surface impair DM action on HLA-DR and -DP near the N terminus of the peptide (Doebele et al., 2000).
in cells and DM-dependent peptide loading in vitro. Two possible complementary surfaces on DM were sug-
The orientation of DM and MHCII predicted by these gested by X-ray structures (Fremont et al., 1998; Mosyak
studies guided design of soluble DM and DR molecules et al., 1998).
fused to leucine zippers via their  chains, resulting How DM alters the shape of the MHCII groove also
in stable DM/DR complexes. Peptide release from the remains unclear. Similar DM effects were observed for
complexes was fast and only weakly sequence depen- peptide/MHCII complexes that differ in intrinsic stability
dent, arguing that DM diminishes the selectivity of (Weber et al., 1996), suggesting that DM may disrupt
the MHCII groove. Analysis of soluble DM action on MHCII H bonds with the peptide backbone. However,
soluble DR/peptide complexes corroborates this con- in other studies, different complexes differ significantly
clusion. in their susceptibility to DM (Hall et al., 2002). Reduced
DM susceptibility has been correlated with optimal P1
anchor/pocket interactions, extended peptide termini,Introduction
and lack of glycines and prolines in the core peptide
(Chou and Sadegh-Nasseri, 2000; Siklodi et al., 1998;Peptide selection by MHCII dictates which antigens are
Raddrizzani et al., 1999).presented to CD4 T cells. The affinity of peptides for
Here we have probed the structure of DM/MHCII com-MHCII is important for peptide selection (McFarland and
plexes by mapping residues important for interaction ofBeeson, 2002). Peptides are held in the MHCII binding
DM with MHCII. The orientation of the two moleculesgroove by two types of interactions. The first involves
predicted by mutagenesis was tested by fusing dimeriz-largely conserved hydrogen (H) bonds between the MHC
ing leucine zipper (LZ) domains to DM and MHCII mole-molecule and the peptide backbone. The second, de-
cules. To explore how DM interaction alters the antigenpendent on peptide sequence and MHCII polymorphism,
binding groove, we measured peptide release from LZ-involves anchor side chains that interact with specificity
stabilized DM/MHCII complexes and analyzed these re-pockets in the groove. However, these interactions are
sults in light of our recent findings with soluble DR/cooperative, and the contributions of particular interac-
peptide complexes exposed to soluble DM (Belmarestions depend on the sequence context.
et al., 2002).In vivo, peptide loading of MHCII is regulated by ac-
cessory molecules (Busch and Mellins, 1996). In the
endoplasmic reticulum, nascent MHCII  dimers rap- Results
idly associate with invariant chain (Ii) to form an ()3Ii3
complex. Residues 90–103 of Ii fill the MHCII groove, DM Mutants Cause CLIP Accumulation In Vivo
To identify DM residues important for interaction withinhibiting ligand binding. Upon transport to late endo-
somes, proteases degrade Ii, leaving a nested set of MHCII, we transduced mutant DMA or DMB cDNAs into
EBV-transformed B cell lines. In one strategy, we mu-peptides called CLIP (class II-associated Ii peptides, Ii
residues 81–104) in the groove. CLIP release is required tated candidate residues and introduced mutant cDNAs
into recipient cell lines lacking the appropriate endoge-
nous DM gene (9.5.3 and 2.2.93, respectively; Figure 1A,*Correspondence: mellins@stanford.edu
left). Transduced cells were screened for CLIP accumu-4 These authors contributed equally to this work.
5 These authors contributed equally to this work. lation, a hallmark of impaired DM action (Figures 1B–1D).
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Figure 1. Identification of DM Mutations that
Elevate CLIP
(A) Transfection strategies for site-directed
and random mutagenesis. (Left) Retrovirus-
mediated introduction of mutant (*) DMB
cDNAs into DMB0 9.5.3 cells or mutant DMA
cDNAs into DMA0 2.2.93 cells results in ex-
pression of DM heterodimers with defined
point mutations. (Right) Expression of ran-
domly mutagenized DMA or DMB cDNAs in
excess in DM 8.1.6 cells allows efficient dis-
placement of the corresponding endogenous
wild-type chain during DM dimer assembly.
(B) Assessment of CLIP accumulation by
FACS analysis. Fully selected populations of
transfectants or untransfected controls were
stained with anti-DR (L243; shaded histo-
grams), anti-CLIP (CerCLIP.1; solid lines), or
without primary antibody (dotted lines). In
8.1.6 cells, introduction of wt DMB (but not
DMA) diminished CLIP levels, suggesting res-
cue of excess endogenous  chain. Examples
from different experiments are shown.
(C and D) Summary of relative CLIP accumu-
lation in 9.5.3 cells transduced with mutant
DMB (C) and in 2.2.93 cells transduced with
mutant DMA cDNAs (D). Background-sub-
tracted CLIP to DR fluorescence ratios were
measured as in (B), and the fold increase in
this ratio over that for the appropriate wt
transfectant is shown for each mutant. Gray
bars represent mutants targeting surface-
exposed charged and hydrophobic residues.
Crosshatched bars indicate mutations filling
the vestigial P4 pocket. Black bars represent
site-directed mutants derived from sequenc-
ing of high-CLIP clones from the random mu-
tant libraries. Each mutant was analyzed at
least twice and usually five to seven times;
2.5-fold changes in CLIP accumulation rela-
tive to wild-type were considered meaningful.
The dysfunction of mutant S9M suggested
by its slight CLIP elevation was not corrobo-
rated in vitro (Figure 2A).
In a complementary strategy, we generated retroviruses the DMA mutations tested conferred a clear high-CLIP
phenotype in 2.2.93 cells (Figure 1D), even though twocarrying DMB or DMA cDNAs with random mutations.
Mutant libraries were expressed in DMA, DMB 8.1.6 (I173N, N195S) originated from the dominant-negative
screen. The higher CLIP level in 2.2.93-DMA wt cellscells, where they competed for one or the other endoge-
nous wild-type (wt) chain (Figure 1A, right). This domi- compared to 9.5.3-DMB wt (Figure 1B), likely due to
lower DM (Figure 2C), made detection of weak pheno-nant-negative strategy was aimed at reducing isolation
of assembly mutants and was possible because the ret- types more difficult. Intriguingly, one mutation, F100A,
reproducibly conferred a lower level of CLIP than wtroviral promoter drove sufficient expression to displace
most of the endogenous wt chain (data not shown). Rare DMA, suggesting that it improved CLIP release.
To assess the abundance, assembly, and conforma-cells with elevated CLIP were cloned and reanalyzed for
surface CLIP (Figure 1B). The mutant cDNAs expressed tional integrity of the mutant DM dimers, we analyzed
their expression. Cells harboring Q100P had low levelsby these clones were sequenced to identify mutations
that might impair DM function. cDNAs carrying individ- of endogenous  chains with an immature glycosylation
pattern, suggesting defective chain pairing and/or ERual point mutations were then introduced into DMB0
(9.5.3) or DMA0 (2.2.93) cells and rescreened for elevated retention (data not shown). Cells expressing N195S
also had low  levels (data not shown), which may ex-CLIP (Figures 1C and 1D).
Together, these strategies identified seven DMB mu- plain its modest in vivo CLIP increase (Figure 1D) and
initial selection in the dominant-negative screen. In thetations that elevated CLIP to varying extents (E8K,
G17V, D31K, E47R, A55V, Q100P, R110S; Figure 1C). other mutants, levels of DM heterodimers were mea-
sured by DM immunoblots of DM immunoprecipitatesOther mutations failed to confer this phenotype, includ-
ing W120R, located on a putative interaction surface (Figures 2A and 2B). Using this semiquantitative assay,
we observed normal levels of DM dimers (less than(Mosyak et al., 1998; Faubert et al., 2002), as well as
mutations (S9M, S9Y, F22W) designed to fill the vesti- 1.5-fold different from wt) for mutants E8K, C46S,
R110G and S, and F100A, less than 3-fold reducedgial P4 pocket of DM (Mosyak et al., 1998). None of
DM/MHCII Interaction
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Figure 2. Expression of Mutant DM Mole-
cules
(A) Semiquantitative assay for DM chains.
DM chains were immunoprecipitated from
cell extracts and associated DM chains
were detected by immunoblotting.
(B) Expression of mutant DM dimers, de-
termined by densitometric analysis of blots
similar to those shown in (A). Means  SEM
are shown for determinations from dilutions
within one experiment. Each mutant was ana-
lyzed at least twice with similar results.
(C) Reactivity with the conformation-sensitive
mAb, MaP.DM1, measured by intracellular
staining and flow cytometry. Fluorescence
histograms are shown for DMB0 9.5.3 and
DMA0 2.2.93 cells as negative controls, and
for retroviral transfectants carrying wt DMA
and DMB cDNAs.
(D) Expression of MaP.DM1-reactive DM mol-
ecules, determined by intracellular flow cy-
tometry as in (C). Expression is normalized to
the corresponding wt transfectant; mean 
SEM values of two to twelve independent de-
terminations are shown for each mutant.
levels for D31K, E47R, and I173N, and a 4-fold re- proportional to the reduced expression of the mutant
dimers (Figure 2) but may be due to conformationalduction for G17V and A55V. A similar hierarchy was
observed by intracellular staining with the conformation- changes (Figures 2B and 2D). For E8K, D31K, E47R,
R110S, F100A, and I173N, expression was onlysensitive anti-DM antibody, MaP.DM1. (Figures 2C
and 2D). However, MaP.DM1 staining of R110G and S moderately effected (Figure 2), and peptide exchange
was not restored at increased concentrations; thus,and I173N was somewhat higher and staining for
E47R lower than expected based on immunoblots; mu- these mutations likely affect interaction with DR directly
(although we cannot exclude subtle conformational ef-tant A55V lost MaP.DM1 reactivity completely. These
discrepancies likely reflect the influence of the muta- fects).
In EBV-B cell lines, 20%–30% of DM molecules aretions on MaP.DM1 binding through conformational dis-
tortions or direct disruption of the epitope. Nonetheless, associated with DO, an MHCII-like molecule that is be-
lieved to block DM action (Denzin et al., 1997) but alsowe concluded that all mutants shown in Figure 2 were
sufficiently intact to warrant further study. reported to enhance DM function (Kropshofer et al.,
1998). Immunoprecipitated wt DM-DO complexes were
inactive in our assay, arguing against a cochaperone
Mutations Impair Other DM Functions
role for DO (data not shown). Differential interactions
To evaluate the effects of these mutations in vitro, immu-
with DO did not explain the functional effects of the DM
noprecipitated mutant DM molecules were tested for
mutations. Except for the underexpressed I173N and
their ability to promote binding of a biotinylated peptide,
E47R mutants, none affected DO steady-state levels
human chondrocyte glycoprotein 39 (HCgp39)262–276, to (DO accumulation in cells is believed to require associa-
recombinant DR0402 molecules (or bio-CLIP81–99 binding tion with DM (Liljedahl et al., 1996). Furthermore, a simi-
to DR3) (Figures 3A–3F). All DMB mutations that elevate
lar fraction of most mutant DM molecules coprecipitated
CLIP in vivo also impaired DM-dependent peptide bind-
with DO, except for R110S, which coprecipitated at
ing in vitro. DMB mutations that are innocuous in vivo
greatly reduced levels (Figure 3G). Thus, the deleterious
also did not affect DM-dependent peptide binding reac-
effects of the DM mutations on DR/peptide exchange
tions in vitro (Figures 3B and 3D). This was true for most
are not due to increased inhibition by DO.
DMA mutations tested as well (Figure 3A). However, for
We also examined the effects of some DMB mutations
two, the situation was more complex (Figures 3A and
on DP. The DP4 allele does not accumulate CLIP in
3F). Mutant I173N entirely lost peptide exchange activ-
the absence of DM (data not shown). Surface DP is
ity in vitro. The F100A mutation, which improved CLIP
increased 2-fold by DM transfection (Figure 3H), per-
release in vivo, paradoxically abrogated DM-dependent
haps due to chaperoning. Mutants E8K, D31K, E47R,
peptide loading in vitro. This mutation may prevent tight
and R110S were impaired in their ability to rescue
peptide binding by stabilizing DM/DR complexes, but
steady-state DP levels. These mutations thus have par-
this remains to be tested.
allel effects on DR and DP phenotypes.
To further evaluate mutants with reduced catalytic
potential, we tested their function across a range of
concentrations (Figures 3C–3F). For G17V, the reduc- Modeling the DM/DR Complex
To examine whether the informative DM mutations iden-tion in function was approximately proportional to the
reduction in input DM (Figure 2 and data not shown), tified an interaction surface, we mapped them on the
crystal structure of HLA-DM (Figure 4). All six are surfacearguing that this mutation did not directly disrupt DM/
DR interaction. The profound defect of A55V was dis- exposed and located on the same lateral face of DM,
Immunity
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Figure 3. DM Mutations Impair Catalysis of
Peptide Binding and DM-Dependent DP Res-
cue but Not DM/DO Association
(A–F) Wt or mutant DM molecules were immu-
noprecipitated via their DM cytoplasmic
tails and tested for catalysis of peptide bind-
ing to DR molecules (see Experimental Proce-
dures).
(A and B) Summary of the effects of selected
DMB (B) or DMA (A) mutations on peptide
binding. DM was immunoprecipitated from
wt or mutant DM transfectants or from DM
null cells as controls. Peptide binding was
expressed as a fraction of that observed with
wild-type DM after subtracting spontaneous
peptide/DR binding in the presence of DM
null precipitate. Error bars show SEM of two
to nine independent experiments.
(C–F) DM immunoprecipitates were prepared
from varying numbers of DMA (F) or DMB
(C–E) transfectants and added to peptide
binding reactions. Controls without DR
gave 3000 counts, so the background seen
with precipitates from untransfected 9.5.3 or
2.2.93 cells mostly reflects spontaneous pep-
tide binding to DR. Similar results were ob-
tained in at least two independent experi-
ments for each mutant.
(G) Mutant DM molecules stabilize and copre-
cipitate with DO. Cells harboring mutant DM
were subjected to DO immunoprecipitation.
Immunoprecipitates were analyzed for DO
using DOB.L1 and for associated DM using
5C1.
(H) Effect of DMB mutations on surface DP
levels. 5.2.4 transfectants with mutant DMB
chains were stained with mAb to DP and ana-
lyzed by flow cytometry. Error bars show SEM
of three independent experiments.
with E8, D31 and E47 forming part of a conserved -DR1 molecules were purified (Busch et al., 2002). To
acidic cluster (Fremont et al., 1998). In contrast, the assess whether LZ fusion stabilized functional DM/DR
mutations whose functional defects appear due to al- complexes, we tested varying amounts of affinity-puri-
tered expression (G17V, Q100P, N195S) do not map fied LZ-DM or soluble DM (sDM) for their ability to
near this face. promote binding of biotinylated HA (306–318) peptide
The I173N and R110S mutations caused addition to LZ-DR1 or sDR1 molecules at endosomal pH. The
of extra N-linked glycans at residues I173 and N108, need for large amounts of sDM (Figure 5A) or LZ-DM
respectively (Figure 2A and data not shown). Glycosyla- (Busch et al., 2002) to catalyze peptide binding to sDR1
tion likely is responsible for the profound phenotype of reflects inefficient interaction of the soluble ectodo-
R110S because R110G, lacking the glycan, had a mains. In contrast, 3000 less LZ-DM catalyzed pep-
normal phenotype. The concave shape of DM’s interac- tide binding to LZ-DR1, indicating that the LZ domain
tion surface is complementary to the convex interaction interaction stabilized DM/DR complexes. Some enhance-
surface on DR (Doebele et al., 2000). ment was also seen when LZ-DR1 was used as a
substrate for sDM. We tentatively attribute this to elec-
trostatic interaction between the positively charged Chain LZ Fusions Stabilize the DM/DR Complex
Base-P1 LZ domain on DR1 and the negatively chargedThe C termini of the DR and DM chains are closer
epitope tags at the C termini of DM and . At neutralto each other in the modeled complex than any other
pH, the same hierarchy was observed, but catalysis wascombination of C termini. Thus, to test the model, we
less efficient. This pH effect suggested that biologicallyemployed soluble DR and DM molecules whose  chain
relevant complexes were stabilized and that the LZ do-C termini were fused, via short spacers, to complemen-
main and DM/DR ectodomain interactions were inde-tary LZ domains (BaseP1 and AcidP1, respectively; Fig-
ure 4). Properly assembled and secreted LZ-DM and pendent, but did not rule out the possibility that the LZ
DM/MHCII Interaction
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Figure 4. Model of DM/DR Interaction
(Left) Location of mutants, mapped on the
crystal structure of DM (Protein Data Bank
accession code 1HDM). Mutations were color
coded based on their effect on DM expres-
sion, DM/DR interaction, or both. (Right) Struc-
ture of DR3/CLIP with DM interaction mutants
indicated (Doebele et al., 2000). Structures
are oriented so as to juxtapose the interacting
surfaces. All chains are labeled at their C ter-
mini; the DM C terminus is hidden behind
Q100. LZ domain fusion via  chain C termini
is depicted schematically. Molecules were
visualized using WebLab Viewer Lite V3.5
(Molecular Simulations Inc., San Diego, CA).
domains constrain the range of orientations available majority of complexes (Figure 6B). Soluble DM without
during DM/DR binding. LZ domains has far lesser effects on peptide release at
The model predicted that LZ fusion via the  chain C these concentrations (data not shown; Zarutskie et al.,
terminus of DR might stabilize DM/DR complexes less 2001), so the rapid release involved LZ-mediated stabili-
(Figure 4). Indeed, there was little enhancement of zation. Surprisingly, the difference in stability between
LZ-DR1/peptide binding in the presence of LZ-DM CLIP and HA was only10-fold (t1/210 s versus 2 min),
(Figure 5B), although, in the absence of DM, LZ-DR1 suggesting that DM interaction reduced the selectivity
molecules bound similar amounts of peptide as did of the antigen binding groove.
LZ-DR1 and sDR1 (data not shown). LZ-DR1 also did To characterize this effect further, we exposed HA and
not share the increased susceptibility of LZ-DR1 to CLIP complexes to varying concentrations of LZ-DM.
sDM (Figure 5C). The LZ domain in LZ-DR1 was not With 10-fold less DM, the proportion of LZ-DM-suscep-
inaccessible; a mAb to the AcidP1/BaseP1 LZ dimer tible complexes remained the same, whereas the off
coprecipitated LZ-DR1 and LZ-DM from mixtures of rates of both complexes were reduced (Figure 6C). Thus,
both molecules (Figure 5D). However, zippering via the LZ-DM exchanged rapidly between susceptible AMCA-
DR C terminus appears to destabilize the LZ-DM peptide/LZ-DR1 complexes; otherwise, at most 10% of
dimer because a disproportionately low amount of the complexes would have dissociated, or more com-
sDM was coprecipitated. We concluded that LZ-DR1 plex kinetics would be seen. The 10-fold difference in
allowed assembly with LZ-DM, but without stabilizing LZ-DM-dependent dissociation between AMCA-CLIP
a productive DM/DR complex. and AMCA-HA was seen at all DM concentrations tested
(Figure 6D). A 1:1 molar ratio of DM to complex was
Diminished Selectivity of Rapid Peptide Release sufficient to reach maximal off rates (Figure 6D; Table 1),
from DM/DR1 Complexes which presumably represented rates of peptide release
To investigate the effect of DM interaction on peptide from the DM/DR complex. At limiting concentrations,
release, we formed complexes between aminomethyl
the off rates were proportional to the amount of LZ-DM.
coumarin acetic acid (AMCA)-labeled HA and CLIP and
This behavior is consistent with a Michaelis-Menten
LZ-DR1 and tracked their release in real time. Fluores-
model, in which LZ-DM (the enzyme) is in rapid preequi-cence resonance energy transfer (FRET) between tryp-
librium with the AMCA-peptide/LZ-DR1 complexes (sub-tophans of DR and the AMCA fluorophore was used to
strates), followed by a rate-limiting peptide release step:quantify bound peptide (Figure 6; Joshi et al., 2000). In
the absence of DM, we found a 200-fold difference in
kinetic stability between AMCA-HA and AMCA-CLIP
DM  DR1/peptide ←→KM DM/DR1/peptidebound to LZ-DR1 (t1/2 	 1 month versus 4 hr; Figure
6A and Table 1). When an equimolar amount of LZ-DM
was added, dissociation was greatly accelerated for the →kcat DM/DR1  peptide. (1)
Immunity
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Does the apparent loss of selectivity of the MHCII
groove in DM/DR complexes also occur in the absence
of LZ domains and with other peptide/DR complexes?
Without LZ stabilization, the low affinity of soluble DR
or DM ectodomains for each other precluded direct
measurement of kcat or of peptide release from 1:1 DM/
DR/peptide complexes. Instead, we exploited the fact
that when substrate concentrations are low compared
to KM, the rate law simplifies to kobs 	 kin  j kin [DM],
where kobs is the observed dissociation rate constant in
the presence of DM and j is a concentration-indepen-
dent measure of DM susceptibility (Weber et al., 1996).
If DM has no effect on the selectivity of the antigen
binding groove, the rate enhancement by DM, and hence
j, should not vary systematically with intrinsic stability.
In contrast, if the groove becomes less selective upon
interaction with DM, then stability differences between
peptide/MHCII complexes should be less pronounced
in the presence of DM, and DM susceptibility (j) should
decrease as kin increases. We have recently measured
peptide release rates for a large number of different
peptide/DR complexes in the presence and absence
of soluble DM (Belmares et al., 2002). The complexes
ranged in intrinsic stability (t1/2) from hours to months;
they represented four different DR alleles, bound to a
large panel of CLIP variants and peptides derived from
self- or foreign antigens. In Figure 6F, we show that
values of j vary over three orders of magnitude for these
complexes. When stratified for high, intermediate, or
Figure 5. LZ Modification of DR1 and DMStabilizes DM/DR Com- low intrinsic stability (low, intermediate, or high kin), thereplexes
was substantial variation in j for each group. Nonethe-
(A) Stabilization of physiologic DM/DR1 complexes by  chain LZ
less, there was a significant trend toward lower valuesfusion. Binding of bio-HA (307–319) to DR molecules in the presence
of j for less stable complexes, seen for all four DR allelesof the indicated doses of DM molecules was measured at pH 4.7
(Belmares et al., 2002). We concluded that the ability of(open symbols) or pH 7.0 (filled symbols). Squares, LZ-DM and
LZ-DR1; circles, sDM and LZ-DR1; triangles, sDM and sDR1. DM to diminish the selectivity of peptide release from
Spontaneous peptide binding in the absence of DM (35,000–65,000 the MHCII groove is not an artifact of LZ stabilization
counts, depending on pH) was subtracted. The experiment was and appears to be a general feature of DM/MHC II inter-
done twice with similar results.
actions.(B and C) Inefficient stabilization of functional DM/DR complexes by
BaseP1 LZ domain fusion via the DR C terminus. Peptide binding
assays were performed at pH 4.7 as in (B), using LZ-DR1, (), Discussion
purified sDR1 (), or purified LZ-DR1 (). (B) Peptide binding to
10 nM DR molecules in the presence of varying amounts of LZ-DM. By mutagenesis, we identified ten individual residues
(C) Peptide binding in the presence of sDM. Similar results were
that are critical for normal DM function. While mutantsobtained in four experiments, using concentrated insect superna-
G17V, Q100P, and N195S primarily alter DM assem-tants (matched for DR content) or purified material as a source of
bly or expression, the other residues cluster on or nearLZ-DR1.
(D) LZ-DR1 assembles with LZ-DM via the LZ domains. LZ-DM a common lateral surface of the molecule (Figure 4),
was mixed with LZ-DR1 or with LZ-DR1 and immunoprecipitated implicating this surface in direct or indirect interaction
using a mAb against the AcidP1/BaseP1 LZ dimer (2H11), or normal with MHCII molecules during peptide exchange. The
mouse Ig (mock). Precipitates were analyzed by immunoblotting
design of LZ domain-stabilized DM/DR1 complexesusing CHAMP (top, anti-DR/) and 5C1 (bottom, anti-DM). Note
based on this information and the shape complementar-that in LZ-DR1, the  and LZ-fused  chain comigrate. Blotting
ity of the candidate MHCII-interacting surface with thewith SU36 (anti-DM/) indicated partial loss of  but not  chain of
LZ-DM from 2H11 coprecipitates with LZ-DR1 (data not shown). DM-interacting face of DR strongly suggest a direct in-
teraction. Precise modeling of the interactions within
the DM/MHCII complex remains difficult, however. Mu-
tations that introduce large glycan moieties at the inter-Indeed, when we measured initial off rates for varying
concentrations of both complexes in the presence of face (R110S, I173N) cannot provide fine structural
detail. Mutants A55V and E47R may act indirectly,catalytic amounts of LZ-DM, good fits to Michaelis-
Menten models were observed (Figure 6E). Importantly, e.g., via nearby acidic residues. Finally, the decreased
selectivity of peptide release from the DM/DR complexkcat values for the peptide/LZ-DR1 complexes differed
by only 10-fold and were similar to the off rates mea- described here suggests that the conformation of the
MHCII groove may be altered more substantially by in-sured at equimolar amounts of LZ-DM (Table 1), con-
sistent with kcat reflecting the rate-limiting peptide re- teraction with DM than was previously appreciated.
Our data agree with available information about thelease step.
DM/MHCII Interaction
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Figure 6. Rapid, Nonselective Peptide Re-
lease from DM/DR Complexes
In (A–E), LZ-DR1 complexes with AMCA-
labeled variant HA (closed circles) or CLIP
(open triangles) peptides were formed over-
night and allowed to dissociate at pH 5.1 in
the presence of excess unlabeled competitor
peptide. Dissociation was monitored by real-
time FRET. Kinetic parameters are summa-
rized in Table 1.
(A) Spontaneous peptide release from LZ-
DR1 (100–200 nM initial complex) in the ab-
sence of DM. Lines represent single-expo-
nential fits to the data.
(B and C) Peptide release from LZ-DR1
(100–200 nM initial complex) in the pres-
ence of equimolar (B) or substoichiometric
amounts (10 nM; [C]) of LZ-DM. Some 30%
of the complexes (15%–50%, depending on
the DR preparation) failed to undergo LZ-
dependent peptide release, regardless of the
DM concentration. We attribute this to steric
inaccessibility of the LZ domain in the resis-
tant subpopulation; immunoblots revealed no
significant proteolysis of the LZ domains
(data not shown).
(D) Rate constants, kd, for LZ-dependent dis-
sociation of susceptible AMCA-HA/LZ-DR1
(100 nM) and AMCA-CLIP/LZ-DR1 (200 nM)
complexes in the presence of varying
amounts of LZ-DM.
(E) Michaelis-Menten kinetics. Varying con-
centrations of peptide/LZ-DR1 complexes
were allowed to dissociate with or without 1 nM LZ-DM. Initial LZ-DM-catalyzed off rates were plotted after subtraction of background
dissociation without LZ-DM.
(F) Susceptibility of 35 different soluble peptide/DR2 and DR4 complexes to soluble DM. Dissociation was measured with or without soluble
DM (Belmares et al., 2002). Complexes were grouped according to their intrinsic stability, as measured by kin, the dissociation rate constant
in the absence of DM. DM susceptibility was measured by the concentration-independent parameter, j 	 (kobs/kin 
 1)/[DM], where kobs is the
dissociation rate constant measured in the presence of a given amount of DM. Horizontal lines indicate medians. The trend toward decreased
j at higher kin across all groups is significant (p  0.0001 by one-way ANOVA with posttest for linear trend for log j) and does not vary strongly
by DR allele (Belmares et al., 2002). One complex with high intrinsic stability and atypical DM resistance was omitted from this analysis.
DM/MHCII interaction. Informative mutants lie along the The DM mutations had effects on DR and DP, largely
without affecting interactions with DO. This interaction,length of DM, consistent with the elongated shape of
the complementary face of DR (Doebele et al., 2000) which is more difficult to disrupt with detergents
(Liljedahl et al., 1996), may also be less sensitive to DMand with a requirement for membrane anchoring for
optimal DM/MHCII interaction (Weber et al., 2001). Stud- mutations. Nonetheless, the ability of the DMB glycosyl-
ation mutant to diminish DM/DO interaction supportsies using a peptide tethered to C46 on the same face
of DM (Stratikos et al., 2002) also agree with the orienta- the contention that the binding sites are overlapping.
The rates of peptide release from DM/DR1 complexestion of the complex proposed here. Both site-directed
and random mutagenesis of DM and  failed to identify suggest substantial changes in the DR1 groove induced
by DM binding. Despite modest turnover numbers, DMadditional binding sites, suggesting that DM has one
binding site for a single MHCII molecule, as previously enhances peptide release by 3–5 orders of magnitude
(Table 1), more than typically seen upon disruption ofproposed based on molecular sizing (Sanderson et al.,
1996). The mutations that alter DM function corroborate the conserved H bond network by mutation (McFarland
and Beeson, 2002). Due to cooperativity effects, disrup-prior evidence for charge and hydrophobic interactions
between DM and DR (Doebele et al., 2000; Ullrich et al., tion of H bonds has the greatest effect on unstable
MHCII/peptide complexes, whereas the opposite is true1997; Sloan et al., 1995).
Protonation of acidic residues on both DM and DR at for DM action: the greatest rate enhancements are seen
for the most stable complexes, and DM interaction par-endosomal pH may relieve charge repulsion and may
allow greater exposure of hydrophobic residues and/or tially collapses differences in dissociation rates. Thus,
although disruption of conserved H bonds likely playsformation of hydrogen bonds at the interface. Com-
plexes of MHC molecules with other ligands share some a role in DM action, DM apparently does not act exclu-
sively by this mechanism but also alters sequence-of the features described here for DM. Examples include
a similarly located acidic cluster at the Fc contact surface dependent peptide/MHCII interactions, resulting in a
binding site with diminished selectivity.of rat neonatal Fc receptor (Burmeister et al., 1994) and
the concave surfaces of classical MHC class I molecules Importantly, both the comparison of LZ-stabilized
DM/DR1 complexes with CLIP and HA and the averageinteracting with CD8 (Gao et al., 1997) and Ly49 (Tormo
et al., 1999). relationship between intrinsic stability and DM suscepti-
Immunity
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Table 1. Kinetic Parameters for Spontaneous and LZ-DM-Catalyzed Release of AMCA-HA and AMCA-CLIP from LZ-DR1
Parameter AMCA-HA AMCA-CLIP CLIP/HA Ratio
kin, no DM (s
1)a 2.98 ( 1.13)  10
7 5.66 ( 0.78)  10
5 192
(n 	 15) (n 	 18)
t1/2, no DM 30.3 d 3.5 hr
kd, 1:1 DM:pep/DRb 0.5  10
2 7.4  10
2 15
t1/2, equimolar 142 s 9.4 s
Fold DM effect 16,000 1300
kcat (s
1)c 1.2 ( 0.66)  10
2 8.1 ( 0.2)  10
2 6.9
(n 	 3) (n 	 2)
t1/2, Michaelis-Menten 60 s 8.6 s
Fold DM effect 40,000 1400
KM (M)c 4.7 ( 1.1)  10
8 9.2 ( 0.4)  10
8 2.0
(n 	 3) (n 	 2)
a Spontaneous off rates (kin) and half-lives (t1/2 	 ln(2)/kin) for AMCA-HA and -CLIP complexes with LZ-DR1 in the absence of LZ-DM were
determined by fitting data to single-exponential decay models (Figure 6A). For HA, initial dissociations were tracked over 1–4 days; derived
rate constants were independent of initial concentration (data not shown). A 3-week dissociation curve showed comparable kinetics; a
fraction of the complexes may dissociate even more slowly (data not shown). Rates of AMCA-HA release from soluble DR1 without LZ domains
were similar (1.8–3.5  10
7 s
1, n 	 2). Lower stability was reported previously for AMCA-HA bound to E. coli-derived soluble DR1 (Zarutskie
et al., 2001) and for related HA peptides at pH 5 or 7 (Sloan et al., 1995; Roche and Cresswell, 1990; Joshi et al., 2000; Stratikos et al., 2002).
Different sources of DR, structures of peptide analogs, assay conditions, and control of proteolysis may all contribute to the discrepancies.
b Off rates, kd, for 1:1 complexes between AMCA-peptide/LZ-DR1 and LZ-DM were determined from the fast phase of the dissociation
curves shown in Figures 6B and 6C. Each complex was analyzed twice with similar results.
c KM and kcat were determined by nonlinear least-squares fit of initial off rates to a Michaelis-Menten model, Rate 	 kcat [DM] [DR/peptide]/
(KM  [DR/peptide]) (Figure 6E). Note that KM values for AMCA-HA and AMCA-CLIP were similar, even though in previous studies, DM
coprecipitated better with MHC II molecules carrying loosely bound peptides such as CLIP (Kropshofer et al., 1997; Denzin et al., 1996; R.B.
and H.M. Scott, unpublished data). The latter results may reflect better DM association with empty MHC II molecules generated by release
of peptide during the experiment, rather than with the peptide/DR complexes themselves; in contrast, KM measures DM’s affinity for the intact
complex.
9.5.3, lacks expression of DM (Morris et al., 1994); the relatedbility for multiple soluble peptide/DR2 or DR4 complexes
mutant 2.2.93 (gift of S. Fling, Corixa Corporation, Seattle, WA) lacksshow a common quantitative relationship: an100-fold
DM (Fling et al., 1994). The 8.1.6 derivative, 5.2.4, has an additionaldifference in intrinsic stability is associated with only an
deletion spanning the entire MHC on the other chromosome; the
10-fold difference in DM susceptibility. This strongly only expressed MHCII allele is DP4 (Mellins et al., 1991; Morris et
suggests that the common trend reflects a genuine al., 1994). 5.2.4/DR3 transfectants have been described (Doebele
et al., 2000). φNX-A is a retroviral vector packaging line (Kinsellaproperty of DM/DR interactions rather than an artifact
and Nolan, 1996). S2 D. melanogaster transfectants expressing solu-of the particular system used.
ble, full-length, and LZ-fused DM and DR molecules have beenIf DM can dissociate extremely stable peptide/MHCII
described (Sloan et al., 1995; Busch et al., 2002; Hall et al., 2002).complexes and presented peptides are not absolutely
DM resistant, how are peptides selected for presenta-
tion? The exposure to DM in endosomes is very likely cDNA Constructs and Transfection
Wild-type cDNAs for DMA*0101 and DMB*0101 were PCR amplifiedlonger (Marsh et al., 1992; Guerra et al., 1998) than the
with Pfu polymerase from pRM-DMA and pRM-DMB (gift of D. Zaller,1–2 min t1/2 of DM/DR1/HA, arguing that the DM effect
Merck Research Laboratories, Rahway, NJ), using the primers, DMA-is not regulated primarily by endosomal transit time.
U1 (GGGTTGGGATCCCCTACCTACTGTGTGGCAAGA) and DMA-L1
Instead, DM and MHCII levels may be modulated to (CCTCTGGAATTCTGGCCGAAGCTGCTGGCATCA) for DMA, DMB-
ensure efficient CLIP release while avoiding excessive U1 (GACTGAGAATTCGGCATCTTTACAGAGCAGAGC) and DMB-L1
(CATCATGTCGACTTGAATCTCCTTCTCACTTGG) for DMB. PCR pro-editing of stable peptides. DM expression is substoichi-
ducts were cloned into retroviral pBMN-IRES vectors containingometric in peptide loading compartments (Ramachan-
neomycin (Neo) or blasticidin (Blasti) resistance genes (Kitamura etdra et al., 1996; Schafer et al., 1996; Glazier et al., 2002).
al., 1995), using primer-encoded restriction sites. Random mutagen-Further, most DM molecules may be engaged in stabiliz-
esis was done by error-prone PCR (Doebele et al., 2000); mutant
ing empty molecules, rather than in peptide editing (Den- DMA and DMB libraries (105 colonies each) were subcloned into
zin et al., 1996). Under these conditions, quantitative pBMN-IRES vectors. Eleven to twelve random clones from each
library were sequenced to determine mutation rates. Based on thedifferences in DM susceptibility may determine the fate
Poisson distribution, 34% DMA and 29% of DMB clones containedof particular peptide/MHCII complexes. DM susceptibil-
single point mutations. All possible single mutations were repre-ity is modestly correlated with increased intrinsic stabil-
sented 46- and 36-fold in the DMA and DMB library, respectively.ity, but other undefined factors contribute (Belmares et
Site-directed mutagenesis was done by overlap extension PCR
al., 2002). The rules governing DM susceptibility will using Pfu polymerase. Mutant cDNAs, cloned into pBMN-IRES-Neo
need to be elucidated for a full understanding of immu- (for DMB) and pBMN-IRES-Blasti (for DMA), were sequenced and
20 g (for libraries) or 8 g (for site-directed mutants) were trans-nodominance.
fected into EBV B cells as described (Doebele et al., 2000).
Construction, insect cell expression, and purification of solubleExperimental Procedures
DM and DR1 molecules, fused to complementary AcidP1 and
BaseP1 LZ domains via their  chain C termini (LZ-DM and LZ-DR1,Cells
The Epstein-Barr virus (EBV)-transformed B cell line, 8.1.6, is DR/ respectively) were as described (Busch et al., 2002). A truncated
DRA cDNA (1 and 2 domains) was similarly fused at the C terminusDQ/DMB-hemizygous but harbors two copies of DMA; its derivative,
DM/MHCII Interaction
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to the BaseP1 zipper via an 8 amino acid spacer (GGGSGGGS) LZ-DM. Dissociations were performed in black, flat-bottom 96-well
polypropylene plates (Greiner, Longwood, FL) sealed with UV-trans-and expressed in S2 cells with soluble DRB1*0101 cDNA, and the
LZ-DR1 molecules were purified by affinity chromatography. parent tape (VIEWseal, Greiner) for longer experiments. Fluores-
cence was recorded with excitation at 280 and 354 nm and emission
at 450 nm, using a Gemini XS multiwell fluorometer (Molecular De-Generation and Characterization of DM Mutant Cells
vices, Sunnyvale, CA). The ratio of background-subtracted FRETDrug-resistant 8.1.6 cells harboring mutant DM libraries were FACS
fluorescence (F280→450) to AMCA fluorescence (F354→450) was 0.2 forsorted for elevated CLIP, and the brightest 0.5%–1% cells were
free and1.45 for bound peptide, allowing estimation of the fractioncloned at one cell/well. Clones were expanded and rescreened by
of bound peptide. For Michaelis-Menten kinetics, peptide/DR com-FACS for surface CLIP and total DR  dimers, using CerCLIP.1
plexes were quantified by AMCA fluorescence, standardized against(Avva and Cresswell, 1994) and L243 (Lampson and Levy, 1980),
a known amount of AMCA peptide (Joshi et al., 2000).respectively. Mutant DM cDNAs were rescued by RT-PCR and se-
To measure susceptibility of peptide/soluble DR complexes toquenced. Single point mutations were created for random mutants
soluble DM, dissociation of fluoresceinated peptides from DR waswith multiple mutations. Site-directed mutants were retrovirally
followed using a size exclusion chromatography assay (Belmares ettransduced into 2.2.93 (for DMA mutants) and 9.5.3 (for DMB mu-
al., 2002). Except for the absence of Tween and protease inhibitors,tants). Drug-resistant polyclonal populations grown in 1 mg/ml G418
conditions were similar to those in the real-time FRET assay. Single-(Life Technologies, Grand Island, NY) or 2–4 g/ml blasticidin S HCl
exponential dissociation rate constants, kobs and kin, were deter-(Calbiochem, San Diego, CA) were screened for elevated CLIP. To
mined in the presence or absence of 0.25 M DM, respectively,analyze surface DP4 levels, cells were stained with B7/21.2 (Robbins
and used to calculate j, a measure of DM susceptibility, using theet al., 1987).
relationship, kobs 	 kin  j kin [DM] (Weber et al., 1996).DM expression was measured in cell extracts (5  106 cells in
buffer containing 1% IGEPAL CA-640), by immunoprecipitation us-
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